Upadacitinib for the treatment of moderate-to-severe atopic dermatitis in real-world clinical practice

被引：0
|
作者：
Tran, Vanessa [1 ]
Ross, Gayle [2 ]
机构：
[1] Melbourne Hlth, Melbourne, Vic, Australia
[2] Royal Melbourne Hosp, Melbourne, Vic, Australia
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2023年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [1] The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan
    Hagino, Teppei
    Saeki, Hidehisa
    Kanda, Naoko
    [J]. JOURNAL OF DERMATOLOGY, 2022, 49 (11): : 1158 - 1167
  • [2] Real-world experience of dupilumab in the treatment of moderate-to-severe atopic dermatitis
    Kim, Nicole S.
    Maliyar, Khalad
    Oliveira, Luciana
    O'Toole, Ashley
    Gooderham, Melinda J.
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2020, 59 (10) : E361 - E363
  • [3] Efficacy of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis in Real-World Practice in a Single Center
    Bai, Juan
    Su, Wang
    Fang, Hong
    Qiao, Jianjun
    [J]. AMERICAN JOURNAL OF THERAPEUTICS, 2024, 31 (03) : e332 - e334
  • [4] Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study
    Hagino, Teppei
    Hamada, Risa
    Yoshida, Mai
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    [J]. PHARMACEUTICALS, 2024, 17 (04)
  • [5] A real-world Australian experience of upadacitinib for the treatment of severe atopic dermatitis
    Tran, Vanessa
    Ross, Gayle
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 (04) : e352 - e356
  • [6] Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
    Hagino, Teppei
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
  • [7] Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan
    Hagino, Teppei
    Hamada, Risa
    Yoshida, Mai
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    [J]. CLINICAL DRUG INVESTIGATION, 2024, 44 (04) : 261 - 269
  • [8] Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan
    Hagino, Teppei
    Yoshida, Mai
    Hamada, Risa
    Saeki, Hidehisa
    Fujimoto, Eita
    Kanda, Naoko
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
  • [9] Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan
    Teppei Hagino
    Risa Hamada
    Mai Yoshida
    Hidehisa Saeki
    Eita Fujimoto
    Naoko Kanda
    [J]. Clinical Drug Investigation, 2024, 44 : 261 - 269
  • [10] Effectiveness and safety of upadacitinib for moderate-to-severe atopic dermatitis in a real-world setting: A 52-week retrospective study
    Gargiulo, L.
    Ibba, L.
    Piscazzi, F.
    Alfano, A.
    Ingurgio, R. Cascio
    Valenti, M.
    Costanzo, A.
    Narcisi, A.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2024, 38 (02) : e152 - e154
12345